Global InformationBerdazimer sodium information
 | |
| Clinical data | |
|---|---|
| Trade names | Zelsuvmi |
| Other names | SB206 |
| License data |
|
| Routes of administration | Topical |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
|
| DrugBank |
|
| UNII |
|
| KEGG |
|
| ChEMBL |
|
| Chemical and physical data | |
| Formula | Indeterminate[1] |
| Molar mass | Indeterminate[1] |
Berdazimer sodium, sold under the brand name Zelsuvmi, is a medication used for the treatment for molluscum contagiosum.[1] Berdazimer sodium is a nitric oxide releasing agent.[1] It is a polymer formed from sodium 1-hydroxy-3-methyl-3-(3-(trimethoxysilyl)propyl)-1-triazene-2-oxide and tetraethyl silicate.[2]
Berdazimer sodium was approved for medical use in the United States in January 2024.[3][4][5]
- ^ a b c d e "Zelsuvmi (berdazimer) topical gel" (PDF). Archived (PDF) from the original on 19 January 2024. Retrieved 9 January 2024.
- ^ "GSRS". gsrs.ncats.nih.gov. Archived from the original on 8 January 2024. Retrieved 8 January 2024.
- ^ "Drug Approval Package: Zelsuvmi". U.S. Food and Drug Administration (FDA). 2 February 2024. Archived from the original on 11 March 2024. Retrieved 11 March 2024.
- ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 29 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
- ^ "U.S. Food and Drug Administration Approves Zelsuvmi as a First-in-Class Medication for the Treatment of Molluscum Contagiosum". Ligand Pharmaceuticals. 5 January 2024. Archived from the original on 8 January 2024. Retrieved 8 January 2024 – via Business Wire.